Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Summary

This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma. The intervention involved in this study is TAK-228.

Timeline

Start

2017-08-01

Primary completion

2021-07-20

Completion

2024-04-24

Publications

• McGregor BA, Xie W, Adib E, Stadler WM, Zakharia Y, Alva A, Michaelson MD, Gupta S, Lam ET, Farah S, Nassar AH, Wei XX, Kilbridge KL, Harshman L, Signoretti S, Sholl L, Kwiatkowski DJ, McKay RR, Choueiri TK. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 Feb;6:e2100448. doi: 10.1200/PO.21.00448.

Drugs

Indications